Clinical Research Directory
Browse clinical research sites, groups, and studies.
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Sponsor: Chen Suning
Summary
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.
Official title: Comparing the Efficacy and Safety of Reduced-dose Chemotherapy Followed by Blinatumomab Versus hyperCVAD as Induction Therapy for Newly Diagnosed Ph-negative B-ALL: a Multicenter, Radomized, Phase 2 Study
Key Details
Gender
All
Age Range
15 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2024-02-05
Completion Date
2026-12-31
Last Updated
2024-04-04
Healthy Volunteers
No
Conditions
Interventions
Blinatumomab Injection [Blincyto]
Reduced-intensity chemotherapy followed by Blinatumomab
Doxorubicin
HyperCVAD regimen
Locations (1)
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China